Not a bad headache. The two loci that replicated in migraine without aura point at neurons and at blood vessel walls — which is the century-old argument about what migraine is, showing up in the data.
Migraine is a neurological disorder, and the headache is one of its symptoms rather than the thing itself. Migraine without aura — the most common form — brings recurrent disabling head pain with autonomic symptoms: nausea, and an intolerance of light and sound severe enough to send people to a dark room for a day.
It is one of the leading causes of years lived with disability worldwide, and it is routinely described as a headache by people who do not have it.
A 2012 study analysed 2,326 clinic-diagnosed German and Dutch people with migraine without aura against 4,580 matched controls, then tested the leading signals again in 2,508 cases and 2,652 controls.
Two loci replicated convincingly:
Two more, PHACTR1 and ASTN2, were suggestive, and earlier associations near TRPM8 — a cold and menthol receptor — and LRP1 were replicated.
Whether migraine is primarily a disorder of blood vessels or of neurons was argued for most of the twentieth century. The vascular theory dominated, then lost ground to neuronal explanations, and the argument was never settled cleanly.
The first study to identify loci specifically for migraine without aura came back with one gene in each camp: a neuronal transcription factor, and a receptor for vascular signalling. Not a verdict for either side.
This study looked at migraine without aura specifically. Aura — the visual disturbance that precedes the headache in some people — has long been suspected of marking a different biology, and separating the two was how these loci were found at all. Mixing the forms had blurred earlier searches.
Nothing about your own headaches. Migraine is diagnosed from the pattern of attacks — how long they last, what comes with them, what makes them worse — by a doctor taking a history. There is no blood test and no genetic test, and no guideline picks a migraine treatment by genotype.
What has changed for patients in the last decade came from biology rather than from genotyping: CGRP-targeting drugs exist because of work on the peptide released during attacks. That is what a mechanism is worth.
Source. Freilinger et al. (Nat Genet 2012) analysed genome-wide association data from 2,326 clinic-based German and Dutch individuals with migraine without aura and 4,580 population-matched controls, selecting SNPs from 12 loci with two or more SNPs at P < 1 × 10⁻⁵ for replication in 2,508 cases and 2,652 controls. Two loci replicated convincingly: 1q22 in MEF2D (replication P = 4.9 × 10⁻⁴, combined P = 7.06 × 10⁻¹¹) and 3p24 near TGFBR2 (replication P = 1.0 × 10⁻⁴, combined P = 1.17 × 10⁻⁹). PHACTR1 and ASTN2 showed suggestive replication (combined P = 3.20 × 10⁻⁸ and 3.86 × 10⁻⁸). Associations in or near TRPM8 and LRP1, reported previously, were replicated. The authors describe this as the first identification of susceptibility loci specific to migraine without aura.
Position listed here. rs3790455 at the 1q22 MEF2D locus.
Phenotype definition. Cases were clinic-based and diagnosed to International Classification of Headache Disorders criteria for migraine without aura. The narrowing is not incidental — it is what allowed loci to reach significance in a sample this size — and it also limits transfer of these estimates to migraine with aura, which was not studied here.
Clinical use. None. Diagnosis is clinical and no genotype selects acute or preventive therapy. The therapeutic advances of the last decade — CGRP monoclonal antibodies and gepants — derive from neuropeptide pharmacology rather than from these loci.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Migraine comes down to these specific, well-studied positions — not a diagnosis.
Research-derived gene–drug associations only — not a prescription, dosing guide, or medical advice. Always follow your prescriber's guidance.
| Gene | Drug | What the research shows |
|---|---|---|
| CYP2D6 | Amitriptyline and nortriptyline | Amitriptyline is one of the oldest and most used migraine preventives, and its handling depends on two enzymes at once. CYP2C19 converts amitriptyline into nortriptyline, which is itself an active drug, and CYP2D6 clears both. A poor metaboliser at CYP2D6 accumulates more drug than intended and is more likely to stop because of dry mouth, sedation or a racing heart; an ultrarapid metaboliser may never reach a useful level. CPIC recommends avoiding the drug or halving the starting dose at both extremes, and considering a therapeutic drug level if it is used anyway. One caveat matters more here than the recommendation does: the guideline was written for the doses used to treat depression, and migraine prophylaxis typically uses a fraction of them, so how much of this carries over to a 10 mg bedtime dose is genuinely not settled. This is a prescriber’s decision, not something to act on from a raw data file. (CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 update (Clin Pharmacol Ther 2017, PMID 27997040); original guideline PMID 23486447. The guideline addresses antidepressant dosing; its application to migraine prophylaxis at lower doses is not established.) |
The first study to find loci specific to migraine without aura returned one gene from each account — MEF2D, a neuronal transcription factor, and TGFBR2, a receptor central to blood vessel biology. It did not settle the argument, and the honest reading is that both are involved.
Because mixing the two forms had blurred earlier searches. Aura has long been suspected of marking different biology, and narrowing the phenotype is what let these loci reach significance in a sample of this size. It also means these results are about migraine without aura and should not be transferred to migraine with aura.
No. No guideline selects a migraine treatment by genotype. The drugs that changed migraine care recently — the CGRP antibodies and gepants — came from work on the peptide released during an attack, not from genotyping.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.